Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals PR Newswire WILMINGTON, Del., Dec. 2, 2020 WILMINGTON, Del., Dec. 2, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp...
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer PR Newswire DUBLIN, Nov. 18, 2020 DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (Nasdaq:...
BioSpecifics Reports Third Quarter 2020 Financial and Operating Results - Endo acquisition of BioSpecifics expected to close in 4Q20 PR Newswire WILMINGTON, Del., Nov. 9, 2020 WILMINGTON, Del...
Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp. PR Newswire DUBLIN, Nov. 2, 2020 DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioSpecifics Technologies Corp. PR Newswire NEW YORK, Oct. 19, 2020 NEW YORK, Oct. 19, 2020 /PRNewswire/ -- Rowley Law PLLC is...
Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™ PR Newswire DUBLIN, Oct. 19, 2020 -- Endo to acquire BioSpecifics in an accretive all-cash transaction -- DUBLIN, Oct...
BioSpecifics to Present at the Virtual Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit PR Newswire WILMINGTON, Del., Sept. 14, 2020 WILMINGTON, Del., Sept. 14, 2020...
BioSpecifics to Present at the H.C. Wainwright Virtual Healthcare Conference PR Newswire WILMINGTON, Del., Sept. 8, 2020 WILMINGTON, Del., Sept. 8, 2020 /PRNewswire/ -- BioSpecifics Technologies...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
